Background Data on thrombosis and current real-world management strategies for
anticoagulation therapy are scarce but important for understanding current issues and …

Introduction One of the most prominent and concerning complications associated with
coronavirus disease 2019 (COVID-19) is venous and arterial thromboembolisms. The aim of …

Background Data on prophylactic anticoagulation are important in understanding the current
issues, unmet needs, and optimal management of Japanese COVID-19 patients. Objectives …

Background Cardiovascular complications, including myocardial infarction, ischemic stroke,
and pulmonary embolism, represent an important source of adverse outcomes in …

Background Best practice for prevention, diagnosis, and management of venous
thromboembolism (VTE) in patients with coronavirus disease 2019 (COVID‐19) is unknown …

Background Coagulopathy is a common abnormality in patients with COVID‐19. However,
the exact incidence of venous thromboembolic event is unknown in anticoagulated, severe …

A hypercoagulable state associated with coronavirus disease 2019 (COVID-19) has been
well documented and is believed to be strongly supported by a proinflammatory state. The …

Thrombotic complications from COVID-19 are now well known and contribute to significant
morbidity and mortality. Different variants confer varying risks of thrombotic complications …

Abstract Coronavirus disease‐19 (COVID‐19) started in Wuhan, China in December 2019
and spread to all around the world in a short period of time. Hospitalized patients with …

Shortly after the emergence of coronavirus disease 2019 (COVID-19) in late 2019, clinicians
rapidly recognized an apparent association between the disease and both arterial and …